JP2022522004A - 依存症障害の遺伝子治療 - Google Patents

依存症障害の遺伝子治療 Download PDF

Info

Publication number
JP2022522004A
JP2022522004A JP2021550130A JP2021550130A JP2022522004A JP 2022522004 A JP2022522004 A JP 2022522004A JP 2021550130 A JP2021550130 A JP 2021550130A JP 2021550130 A JP2021550130 A JP 2021550130A JP 2022522004 A JP2022522004 A JP 2022522004A
Authority
JP
Japan
Prior art keywords
rvv
vector
nucleic acid
condition
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021550130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522004A5 (https=
Inventor
ウォーレン シー． ラウ，
ブラッド トンプソン，
Original Assignee
パスウェイズ ニューロ ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パスウェイズ ニューロ ファーマ， インコーポレイテッド filed Critical パスウェイズ ニューロ ファーマ， インコーポレイテッド
Publication of JP2022522004A publication Critical patent/JP2022522004A/ja
Publication of JP2022522004A5 publication Critical patent/JP2022522004A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021550130A 2019-02-27 2020-02-27 依存症障害の遺伝子治療 Pending JP2022522004A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811339P 2019-02-27 2019-02-27
US62/811,339 2019-02-27
PCT/US2020/020216 WO2020176796A1 (en) 2019-02-27 2020-02-27 Gene therapy for addiction disorders

Publications (2)

Publication Number Publication Date
JP2022522004A true JP2022522004A (ja) 2022-04-13
JP2022522004A5 JP2022522004A5 (https=) 2023-03-07

Family

ID=72239690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550130A Pending JP2022522004A (ja) 2019-02-27 2020-02-27 依存症障害の遺伝子治療

Country Status (5)

Country Link
US (1) US20220152222A1 (https=)
EP (1) EP3931214A4 (https=)
JP (1) JP2022522004A (https=)
AU (2) AU2020229874A1 (https=)
WO (1) WO2020176796A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11850427B2 (en) * 2019-12-02 2023-12-26 West Virginia University Board of Governors on behalf of West Virginia University Methods and systems of improving and monitoring addiction using cue reactivity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531926A (ja) * 2015-09-17 2018-11-01 コーダ バイオセラピューティクス， インコーポレイテッド 神経学的障害を処置するための組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146898A1 (en) * 1999-01-22 2001-10-24 Matthew John During Vaccine-mediated treatment of neurological disorders
US20070065801A1 (en) * 2003-05-21 2007-03-22 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
GB201404470D0 (en) * 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531926A (ja) * 2015-09-17 2018-11-01 コーダ バイオセラピューティクス， インコーポレイテッド 神経学的障害を処置するための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"UniProt", Q13639, FULL=5-HYDROXYTRYPTAMINE RECEPTOR 4, JPN6024008839, 13 February 2019 (2019-02-13), ISSN: 0005426157 *

Also Published As

Publication number Publication date
EP3931214A1 (en) 2022-01-05
US20220152222A1 (en) 2022-05-19
AU2020229874A1 (en) 2021-09-23
EP3931214A4 (en) 2023-09-13
AU2025248711A1 (en) 2025-11-13
WO2020176796A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
JP7221275B2 (ja) Ａａｖを送達するための組成物および方法
TWI897844B (zh) 調節多核苷酸
US20210395776A1 (en) Frataxin expression constructs having engineered promoters and methods of use thereof
EP3826719A1 (en) Systems and methods for producing gene therapy formulations
AU2018261003A1 (en) Compositions and methods of treating Huntington's Disease
CN117120619A (zh) 用于治疗与葡萄糖神经酰胺酶β缺陷相关的神经病症的组合物和方法
JP2023542211A (ja) 神経疾患を処置するための方法
AU2025248711A1 (en) Gene Therapy For Addiction Disorders
WO2025038802A1 (en) Compositions and methods for the treatment of disorders related to ataxin-2
EP3390623B1 (en) Wilson's disease gene therapy
JP2008523093A (ja) 哺乳類の中枢神経系における導入遺伝子の調節発現
AU2021349261A9 (en) Compositions and methods for inhibiting alpha-synuclein aggregation
JP2023512688A (ja) 脊髄損傷後の機能回復を促進するためのマイクロｒｎａ－７組成物およびその使用方法
WO2021087030A1 (en) Gene therapy approaches to mucolipidosis iv (mliv)
KR102844372B1 (ko) 뇌 성상교세포 특이적 유전자 전달이 가능한 아데노부속바이러스 변이체와 이의 응용
WO2024147114A1 (en) Compositions and methods for treating parkinson's disease
Cheng Pharmacologically controlled neurotrophic factor gene therapy for Parkinson's disease
KR20240017311A (ko) Aav 전달을 위한 조성물 및 aav 전달 효율 스크리닝 방법
JP2026071207A (ja) グルコシルセラミダーゼベータ欠損に関連する神経障害の治療のための組成物及び方法
WO2025038955A1 (en) Systems and methods for improving safety of split intein aav mediated gene therapy
TW202608488A (zh) 基因治療
CN120897996A (zh) 用于治疗与葡萄糖神经酰胺酶β1缺陷相关之神经病症的组合物及方法
HK40095649A (zh) 具有增强的转导效率并在脑中广泛分布的重组腺相关病毒载体的新型工程化衣壳血清型
HK40050637A (en) Compositions and methods for delivery of aav
HK40063258B (zh) 腺相关病毒对cln6多核苷酸的递送

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001